



ADULT MEDICATION GUIDELINE

Nystatin

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

Restrictions

[Formulary: Unrestricted](#)

Medication Class

Polyene antifungal

Presentation

Tablet: 500,000 units

Oral suspension: 100,000 units/mL (24mL)

Cream: 100,000 units/g (15g)

Vaginal cream: 100,000 units/ dose (75 g)

Storage

Store at room temperature, below 25°C

Dose

Vulvovaginal candidiasis

Per vagina:

1 applicatorful intravaginally, once daily for 14 days OR twice daily for 7 days

Candidiasis in pregnancy

Per vagina:

1 applicatorful intravaginally, once daily for 12-14days

Vaginal applicators may be used with care in pregnancy

Recurrent candidiasis

Per vagina:

1 applicatorful intravaginally weekly

Oropharyngeal candidiasis

Oral:

1mL (100,000 units) 4 times daily for 7 to 14 days. Continue to use for several days after symptoms disappear. Higher doses, eg 500 000 units 4 times daily, can be used.

Administration

Oral Liquid

Swirl around mouth for as long as comfortable then swallow. Use after meals/drinks and just before bed.

Vaginal Cream

To be inserted high in the vagina using the applicator provided. Use with care in pregnancy. Vaginal creams are best used at bedtime

Pregnancy

1st Trimester: Safe to use

2nd Trimester: Safe to use

3rd Trimester: Safe to use

Breastfeeding

Safe to use

Comments

Do not use contraceptive diaphragms or condoms during therapy as they may be damaged by nystatin vaginal cream

Clean the applicator after each use

Therapy should be continued during menstruation; use sanitary pads instead of tampons

Extended treatment duration (12-14 days) is required in pregnancy due to lower response rates and more frequent relapse.

Related Policies, Procedures & Guidelines

WNHS Policies:

[Antimicrobial Stewardship \(AMS\) policy](#)

WNHS Clinical Practice Guidelines:

[Vaginal infections: Antibiotic treatment for](#)

References

Australian Medicines Handbook. Nystatin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 May 25]. Available from: <https://amhonline.amh.net.au/>

Australian Medicines Handbook. Vulvovaginal candidiasis. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 May 25]. Available from: <https://amhonline.amh.net.au/>









The Royal Women's Hospital. Nystatin. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021[cited 2021 May 25]. Available from: <https://thewomenspbmg.org.au/>

Therapeutic Guidelines. Candidal vulvovaginitis in women. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2021[cited 2021 May 25]. Available from: <https://tgldcdp.tg.org.au>

MIMS Australia. Nystatin Vaginal. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 [cited 2021 May 25]. Available from: <https://www.mimsonline.com.au>

AusDI [Internet]. St Leonards (NSW): Health Communication Network; c2021. Nystatin Vaginal Cream; [updated 2018 Feb 18; cited 2021 May 25]. Available from: <https://ausdi-hcn-com-au.kelibresources.health.wa.gov.au/productMonograph.hcn?file=0278>

Sexual Health and Blood-borne Virus Program. Non-notifiable infections: Candidiasis. Silver book - guidelines for managing sexually transmitted infections and blood-borne viruses [Internet]. Perth (WA): Government of Western Australia Department of Health; 2015 [updated 2020 May 07; cited 2021 May 25]. Available from: <http://ww2.health.wa.gov.au/Silver-book/Non-notifiable-infections/Candidiasis>.

Keywords	Nystatin, candidiasis, thrush, nilstat, vaginal thrush				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:					
Date First Issued:	31/07/2015	Last Reviewed:	31/01/2018	Review Date:	31/05/2021
Endorsed by:	Medicines and Therapeutics Committee			Date:	19/08/2021
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input checked="" type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.